Agostinho Carvalho graduated in 2003 in Biology from the University of Minho and received a PhD in Health Sciences from the same University in 2008. Between 2009 and 2012, he developed postdoctoral studies on the genetic basis of susceptibility to fungal infection at the Life and Health Sciences Research Institute (ICVS) of the University of Minho, and the University of Perugia, Italy, in the lab of Luigina Romani. In 2012, he became an Assistant Researcher at the Department of Experimental Medicine of the University of Perugia, where he further developed his interests in fungal immunology and immunogenetics until 2014. Later that year, he became an Assistant Researcher (FCT Investigator) and returned to ICVS, where he consolidated his research team. Since 2019, he has been a Principal Investigator (with Habilitation since 2023) at ICVS. He was also nominated Vice-Director of ICVS in 2023. His research activity is focused on the elucidation of the effects of interindividual genetic variation on molecular and cellular processes of immunity and inflammation, and the translation of this information into new and personalized approaches for the prognosis, diagnosis, and therapy of infectious and inflammatory diseases. These aims are being addressed by a multidisciplinary team that combines basic scientists and clinical experts with different degrees of specialization, and that resorts to advanced cellular and animal models of disease and human patients enrolled in national and international consortia. The team is also engaged in collaborations with several international labs on immunology, functional genomics, and the biology of infectious and inflammatory diseases. His track record includes 150 publications in international peer-reviewed journals (>6,600 citations and h-index=40, ISI Web of Knowledge; March 2024), 1 book and 9 book chapters, and a patent on fungal diagnostics. Selected recent publications include senior authorship of papers in Lancet Respir Med 2022, Nat Microbiol 2022, Am J Respir Crit Care Med 2022 and 2024, N Engl J Med 2014, Nat Commun 2020, and JACI 2017, besides relevant collaborations in Lancet Microbe 2024 and 2022, Cell Host Microbe 2023, Nature 2018, Nat Microbiol 2018, Immunity 2013, Cell Metab 2016, and Nat Commun 2021 and 2018. He has been supported by several funding agencies, e.g., H2020, "la Caixa" Foundation, Fundação para a Ciência e a Tecnologia (FCT), European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and contracts with the industry, e.g., Gilead, Mérieux. He has supervised 10 postdoctoral researchers and 12 PhD students, besides multiple MSc and undergraduate students. He is the Chief Specialty Editor for Medical Mycology in Frontiers in Fungal Biology and an editorial board member for Infection and Immunity and Microbiology Spectrum. He has been an ad-hoc reviewer for more than 70 journals and several funding agencies, including the European Commission (e.g., ERC, H2020, MSCA), Wellcome Trust, Agence Nationale de la Recherche (ANR), Ministero dell'Istruzione e del Merito (MIUR), Israel Science Foundation (ISF), and FCT. Because of his contributions to the field, he has received over 70 invitations to speak/chair at established international meetings, and several awards, including the Jon J. van Rood award for outstanding contributions in immunogenetics. He is an elected Fellow of the European Confederation of Medical Mycology (ECMM).